Viropil (PeP)

Viropil is a high-potency, bioequivalent single-tablet regimen (STR) specifically formulated for Post-Exposure Prophylaxis (PEP) and HIV treatment. It combines three critical antiretroviral agents: Dolutegravir (50 mg), Lamivudine (300 mg), and Tenofovir Disoproxil Fumarate (300 mg). Manufactured by Emcure Pharmaceuticals, this "TLD" combination is recognized by the World Health Organization (WHO) as the gold standard for emergency HIV prevention. By integrating a high-barrier integrase inhibitor (Dolutegravir), Viropil provides the most robust protection available to stop the virus from establishing a permanent infection after a potential high-risk exposure.